- The companies launch Nepexto, a biosimilar referencing Amgen’s Enbrel, and is indicated for the mod. to sev. RA, JIA from the age of 2yrs., active and progressive PsA, severe axSpA, mod. to sev. PsO and chronic severe PsO in children and adolescents from the age of 6yrs.
- Nepexto is available as a solution for injection in a pre-filled pen and prefilled syringe and has shown equivalent efficacy and safety to Enbrel
- The EC has approved MAA to Nepexto on Jun 04, 2020, following CHMP’s positive opinion. The approval underlines the scientific success of Mylan’s biologics program and expands Mylan’s therapeutic portfolio for immune-mediated diseases including RA
Click here to read full press release/ article | Ref: Lupin | Image: mAbxience